150 related articles for article (PubMed ID: 16204078)
21. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo.
Arai R; Tsuda M; Watanabe T; Ose T; Obuse C; Maenaka K; Minami A; Ohba Y
Eur J Cancer; 2012 Oct; 48(15):2417-30. PubMed ID: 22244830
[TBL] [Abstract][Full Text] [Related]
22. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
[TBL] [Abstract][Full Text] [Related]
23. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
Seamon JA; Rugg CA; Emanuel S; Calcagno AM; Ambudkar SV; Middleton SA; Butler J; Borowski V; Greenberger LM
Mol Cancer Ther; 2006 Oct; 5(10):2459-67. PubMed ID: 17041089
[TBL] [Abstract][Full Text] [Related]
24. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
27. IPP5, a novel inhibitor of protein phosphatase 1, suppresses tumor growth and progression of cervical carcinoma cells by inducing G2/M arrest.
Zeng Q; Huang Y; Zeng L; Huang Y; Cai D; Zhang H
Cancer Genet; 2012 Sep; 205(9):442-52. PubMed ID: 22939397
[TBL] [Abstract][Full Text] [Related]
28. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.
Thomas HD; Wang LZ; Roche C; Bentley J; Cheng Y; Hardcastle IR; Golding BT; Griffin RJ; Curtin NJ; Newell DR
Eur J Cancer; 2011 Sep; 47(13):2052-9. PubMed ID: 21570822
[TBL] [Abstract][Full Text] [Related]
29. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A.
Liu HS; Ke CS; Cheng HC; Huang CY; Su CL
Mol Pharmacol; 2011 Oct; 80(4):638-46. PubMed ID: 21757545
[TBL] [Abstract][Full Text] [Related]
30. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
31. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
32. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
33. The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells.
Xie F; Lang Q; Zhou M; Zhang H; Zhang Z; Zhang Y; Wan B; Huang Q; Yu L
Eur J Pharm Sci; 2012 Aug; 46(5):388-96. PubMed ID: 22449725
[TBL] [Abstract][Full Text] [Related]
34. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
[TBL] [Abstract][Full Text] [Related]
35. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
McLaughlin J; Markovtsov V; Li H; Wong S; Gelman M; Zhu Y; Franci C; Lang D; Pali E; Lasaga J; Low C; Zhao F; Chang B; Gururaja TL; Xu W; Baluom M; Sweeny D; Carroll D; Sran A; Thota S; Parmer M; Romane A; Clemens G; Grossbard E; Qu K; Jenkins Y; Kinoshita T; Taylor V; Holland SJ; Argade A; Singh R; Pine P; Payan DG; Hitoshi Y
J Cancer Res Clin Oncol; 2010 Jan; 136(1):99-113. PubMed ID: 19609559
[TBL] [Abstract][Full Text] [Related]
36. Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer.
Qu Y; Zhang L; Mao M; Zhao F; Huang X; Yang C; Xiong Y; Mu D
Cancer Gene Ther; 2008 Aug; 15(8):517-25. PubMed ID: 18404163
[TBL] [Abstract][Full Text] [Related]
37. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
38. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Adams ND; Adams JL; Burgess JL; Chaudhari AM; Copeland RA; Donatelli CA; Drewry DH; Fisher KE; Hamajima T; Hardwicke MA; Huffman WF; Koretke-Brown KK; Lai ZV; McDonald OB; Nakamura H; Newlander KA; Oleykowski CA; Parrish CA; Patrick DR; Plant R; Sarpong MA; Sasaki K; Schmidt SJ; Silva DJ; Sutton D; Tang J; Thompson CS; Tummino PJ; Wang JC; Xiang H; Yang J; Dhanak D
J Med Chem; 2010 May; 53(10):3973-4001. PubMed ID: 20420387
[TBL] [Abstract][Full Text] [Related]
39. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
40. LRD-22, a novel dual dithiocarbamatic acid ester, inhibits Aurora-A kinase and induces apoptosis and cell cycle arrest in HepG2 cells.
Wang H; Li R; Li L; Ge Z; Zhou R; Li R
Biochem Biophys Res Commun; 2015 Feb; 458(1):201-7. PubMed ID: 25645017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]